SLC10A2 and inflammatory bowel disease: Through the bile acid signaling pathway, the Apical Sodium-Dependent Bile Acid Transporter (ASBT) encoded by slc10a2 can inhibit inflammation, stimulate the production of anti-inflammatory factors, and promote the regeneration of the epithelial barrier, making it a potential therapeutic target for IBD (29).